<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075151</url>
  </required_header>
  <id_info>
    <org_study_id>DSRB/2013/00144</org_study_id>
    <nct_id>NCT02075151</nct_id>
  </id_info>
  <brief_title>Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype</brief_title>
  <official_title>Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to World Health Organization (WHO) estimates, more than 200 million people suffer
      from asthma worldwide and in 2009, the disease had claimed 250,000 lives globally. Autopsy
      reports suggest 2 phenotypes of severe asthma: one that is characterized by intense airway
      inflammation with mucus plugging, and the other by severe bronchoconstriction causing
      respiratory failure in the absence of significant airway inflammation. However, it is not
      easy to stratify patients according to phenotypes without bronchoscopy. Although severe
      asthma comprises only 10% of affected individuals, it accounts for more than half of the
      total healthcare spending on asthma. Inhaled corticosteroids are effective by suppressing
      production of multiple pro-inflammatory mediators, unfortunately efficacy plateaus. Addition
      of long acting beta agonist and anti-cholinergic agent to inhaled corticosteroids offers some
      measure of relief but effective treatment of severe asthma remains an unmet goal, resulting
      in intensive utilization of healthcare resources. In 2010, the United States Food and Drug
      Administration (FDA) approved bronchial thermoplasty (BT) as an adjunctive therapy for severe
      asthma. BT is radiofrequency ablation of airway smooth muscle via bronchoscopy with each
      patient undergoing three procedures which targets different lobes of the lung 3 weeks apart.
      Studies have demonstrated improved symptom control allowing discontinuation of oral steroids
      in some patients as well as reductions in exacerbations, hospitalizations and use of rescue
      medications. No development of airway strictures or bronchiectasis, and regeneration of
      normal epithelium after BT has been observed. At present, it remains unclear if BT benefits
      all asthma phenotypes or if BT has any effect on airway inflammation and remodeling.

      The hypothesis of this study is that bronchial thermoplasty is likely to benefit all severe
      asthma phenotypes, and achieves this by exerting an effect on airway inflammation and
      remodelling.

      The specific aims of the study are: 1) to better define the asthma phenotype who will benefit
      from BT by microarray and gene expression profiling; 2) to study effects of BT on airway
      inflammation; 3) to define its role in the overall asthma management algorithm
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Test (ACT) score</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of symptom-free days</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled nitric oxide (NO)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-contrast Computed Tomography (CT) scan of the thorax</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Bronchial Thermoplasty</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bronchial thermoplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchial Thermoplasty</intervention_name>
    <description>Bronchial thermoplasty</description>
    <arm_group_label>Bronchial Thermoplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 21-65 years of age

          -  Poorly controlled severe persistent asthma (ACT score &lt; 20) despite high-dose inhaled
             steroids (&gt;500 mcg fluticasone/day or &gt;800 mcg budesonide/day) in combination with
             inhaled long-acting Beta-2 agonist and/or anticholinergic agent. Other drugs include
             leukotriene modifiers, omalizumab (if used for at least 1 year prior), and oral
             corticosteroids 10mg/day or less

          -  Stopped smoking for &gt; 1 year and &lt;10 pack-years

          -  Stable maintenance asthma medications for 4 weeks

          -  Pre-bronchodilator FEV1 &gt;60% predicted

        Exclusion Criteria:

          -  Males and females &lt;21 and &gt;65 years of age

          -  Presence of pacemaker, internal defibrillator, or other implantable electronic devices

          -  Known sensitivity to medications required to perform bronchoscopy, including
             lignocaine and benzodiazepines

          -  Patients previously treated with Bronchial Thermoplasty (BT)

          -  Use of immunosuppressant (excluding oral steroids)

          -  Increased risk of adverse events associated with bronchoscopy or anesthesia (including
             pregnancy, uncontrolled coronary artery disease, acute or chronic renal failure, and
             uncontrolled hypertension)

          -  Inability to cease antiplatelet or anticoagulant therapy prior to procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kay Leong Khoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kay Leong Khoo, MD</last_name>
      <phone>65-67795555</phone>
      <email>khoo_kay_leong@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Kay Leong Khoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pyng Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>HOUSTON JC, DE NAVASQUEZ S, TROUNCE JR. A clinical and pathological study of fatal cases of status asthmaticus. Thorax. 1953 Sep;8(3):207-13.</citation>
    <PMID>13102418</PMID>
  </reference>
  <reference>
    <citation>Kuyper LM, Par√© PD, Hogg JC, Lambert RK, Ionescu D, Woods R, Bai TR. Characterization of airway plugging in fatal asthma. Am J Med. 2003 Jul;115(1):6-11.</citation>
    <PMID>12867228</PMID>
  </reference>
  <reference>
    <citation>Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis. 1991 Jan;143(1):138-43.</citation>
    <PMID>1986670</PMID>
  </reference>
  <reference>
    <citation>Hogg JC. Varieties of airway narrowing in severe and fatal asthma. J Allergy Clin Immunol. 1987 Sep;80(3 Pt 2):417-9.</citation>
    <PMID>3624696</PMID>
  </reference>
  <reference>
    <citation>Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, Hunt LW, Gleich GJ. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis. 1993 Sep;148(3):713-9.</citation>
    <PMID>8368644</PMID>
  </reference>
  <reference>
    <citation>Good JT Jr, Kolakowski CA, Groshong SD, Murphy JR, Martin RJ. Refractory asthma: importance of bronchoscopy to identify phenotypes and direct therapy. Chest. 2012 Mar;141(3):599-606. doi: 10.1378/chest.11-0741. Epub 2011 Aug 11.</citation>
    <PMID>21835905</PMID>
  </reference>
  <reference>
    <citation>Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug 1;178(3):218-224. doi: 10.1164/rccm.200711-1754OC. Epub 2008 May 14.</citation>
    <PMID>18480428</PMID>
  </reference>
  <reference>
    <citation>Wahidi MM, Kraft M. Bronchial thermoplasty for severe asthma. Am J Respir Crit Care Med. 2012 Apr 1;185(7):709-14. doi: 10.1164/rccm.201105-0883CI. Epub 2011 Nov 10. Review.</citation>
    <PMID>22077066</PMID>
  </reference>
  <reference>
    <citation>Lee P, Khoo KL. A review of current bronchoscopic interventions for obstructive airway diseases. Ther Adv Respir Dis. 2012 Oct;6(5):297-307. Epub 2012 Aug 9. Review.</citation>
    <PMID>22878625</PMID>
  </reference>
  <reference>
    <citation>Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA, Zinder N, Levine AJ, Roberts RJ, Simon M, Slayman C, Hunkapiller M, Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington K, Abu-Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R, Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z, Di Francesco V, Dunn P, Eilbeck K, Evangelista C, Gabrielian AE, Gan W, Ge W, Gong F, Gu Z, Guan P, Heiman TJ, Higgins ME, Ji RR, Ke Z, Ketchum KA, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov GV, Milshina N, Moore HM, Naik AK, Narayan VA, Neelam B, Nusskern D, Rusch DB, Salzberg S, Shao W, Shue B, Sun J, Wang Z, Wang A, Wang X, Wang J, Wei M, Wides R, Xiao C, Yan C, Yao A, Ye J, Zhan M, Zhang W, Zhang H, Zhao Q, Zheng L, Zhong F, Zhong W, Zhu S, Zhao S, Gilbert D, Baumhueter S, Spier G, Carter C, Cravchik A, Woodage T, Ali F, An H, Awe A, Baldwin D, Baden H, Barnstead M, Barrow I, Beeson K, Busam D, Carver A, Center A, Cheng ML, Curry L, Danaher S, Davenport L, Desilets R, Dietz S, Dodson K, Doup L, Ferriera S, Garg N, Gluecksmann A, Hart B, Haynes J, Haynes C, Heiner C, Hladun S, Hostin D, Houck J, Howland T, Ibegwam C, Johnson J, Kalush F, Kline L, Koduru S, Love A, Mann F, May D, McCawley S, McIntosh T, McMullen I, Moy M, Moy L, Murphy B, Nelson K, Pfannkoch C, Pratts E, Puri V, Qureshi H, Reardon M, Rodriguez R, Rogers YH, Romblad D, Ruhfel B, Scott R, Sitter C, Smallwood M, Stewart E, Strong R, Suh E, Thomas R, Tint NN, Tse S, Vech C, Wang G, Wetter J, Williams S, Williams M, Windsor S, Winn-Deen E, Wolfe K, Zaveri J, Zaveri K, Abril JF, Guig√≥ R, Campbell MJ, Sjolander KV, Karlak B, Kejariwal A, Mi H, Lazareva B, Hatton T, Narechania A, Diemer K, Muruganujan A, Guo N, Sato S, Bafna V, Istrail S, Lippert R, Schwartz R, Walenz B, Yooseph S, Allen D, Basu A, Baxendale J, Blick L, Caminha M, Carnes-Stine J, Caulk P, Chiang YH, Coyne M, Dahlke C, Mays A, Dombroski M, Donnelly M, Ely D, Esparham S, Fosler C, Gire H, Glanowski S, Glasser K, Glodek A, Gorokhov M, Graham K, Gropman B, Harris M, Heil J, Henderson S, Hoover J, Jennings D, Jordan C, Jordan J, Kasha J, Kagan L, Kraft C, Levitsky A, Lewis M, Liu X, Lopez J, Ma D, Majoros W, McDaniel J, Murphy S, Newman M, Nguyen T, Nguyen N, Nodell M, Pan S, Peck J, Peterson M, Rowe W, Sanders R, Scott J, Simpson M, Smith T, Sprague A, Stockwell T, Turner R, Venter E, Wang M, Wen M, Wu D, Wu M, Xia A, Zandieh A, Zhu X. The sequence of the human genome. Science. 2001 Feb 16;291(5507):1304-51. Erratum in: Science 2001 Jun 5;292(5523):1838.</citation>
    <PMID>11181995</PMID>
  </reference>
  <reference>
    <citation>Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, McDonald VM, Sim A, Gibson PG. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011 Jun 15;183(12):1633-43. doi: 10.1164/rccm.201010-1623OC. Epub 2011 Mar 18.</citation>
    <PMID>21471098</PMID>
  </reference>
  <reference>
    <citation>Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem. 2001;70:437-73. Review.</citation>
    <PMID>11395414</PMID>
  </reference>
  <reference>
    <citation>Naaby-Hansen S, Waterfield MD, Cramer R. Proteomics--post-genomic cartography to understand gene function. Trends Pharmacol Sci. 2001 Jul;22(7):376-84. Review.</citation>
    <PMID>11431033</PMID>
  </reference>
  <reference>
    <citation>Zhao J, Zhu H, Wong CH, Leung KY, Wong WS. Increased lungkine and chitinase levels in allergic airway inflammation: a proteomics approach. Proteomics. 2005 Jul;5(11):2799-807.</citation>
    <PMID>15996009</PMID>
  </reference>
  <reference>
    <citation>Wong WS, Zhao J. Proteome analysis of chronically inflamed lungs in a mouse chronic asthma model. Int Arch Allergy Immunol. 2008;147(3):179-89. doi: 10.1159/000142040. Epub 2008 Jul 2.</citation>
    <PMID>18594147</PMID>
  </reference>
  <reference>
    <citation>Quesada Calvo F, Fillet M, Renaut J, Crahay C, Gueders M, Hacha J, Paulissen G, Foidart JM, Noel A, Rocks N, Leprince P, Cataldo D. Potential therapeutic target discovery by 2D-DIGE proteomic analysis in mouse models of asthma. J Proteome Res. 2011 Sep 2;10(9):4291-301. doi: 10.1021/pr200494n. Epub 2011 Aug 3.</citation>
    <PMID>21751807</PMID>
  </reference>
  <reference>
    <citation>Liao W, Goh FY, Betts RJ, Kemeny DM, Tam J, Bay BH, Wong WS. A novel anti-apoptotic role for apolipoprotein L2 in IFN-Œ≥-induced cytotoxicity in human bronchial epithelial cells. J Cell Physiol. 2011 Feb;226(2):397-406. doi: 10.1002/jcp.22345.</citation>
    <PMID>20665705</PMID>
  </reference>
  <reference>
    <citation>Fitzpatrick AM, Higgins M, Holguin F, Brown LA, Teague WG; National Institutes of Health/National Heart, Lung, and Blood Institute's Severe Asthma Research Program. The molecular phenotype of severe asthma in children. J Allergy Clin Immunol. 2010 Apr;125(4):851-857.e18. doi: 10.1016/j.jaci.2010.01.048.</citation>
    <PMID>20371397</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchial Thermoplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

